Recent Quotes (30 days)

You have no recent quotes
chg | %

Sophiris Bio Inc  

(Public, TSE:SHS)   Watch this stock  
Find more results for TSE:PRX
0.0000
- Close
TSE data delayed by 15 mins - Disclaimer
Currency in
Range     -
52 week 4.25 - 18.20
Open     -
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -4.35
Shares     -
Beta     -
Inst. own     -
Aug 5, 2016
Q2 2016 Sophiris Bio Inc Earnings Release (Estimated) Add to calendar
May 16, 2016
Q1 2016 Sophiris Bio Inc Earnings Release
Mar 23, 2016
Q4 2015 Sophiris Bio Inc Earnings Release
Mar 16, 2016
Sophiris Bio Inc at ROTH Conference
Mar 9, 2016
Sophiris Bio Inc at Cowen Health Care Conference
  

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -121.94% -82.34%
Return on average equity -1053.00% -171.11%
Employees 9 -
CDP Score - -

Address

1258 Prospect St
LA JOLLA, CA 92037-3609
United States - Map
+1-858-7771760 (Phone)
+1-858-4125693 (Fax)

Website links

Description

Sophiris Bio Inc. is a clinical-stage biopharmaceutical company focused on developing products for the treatment of urological diseases. The Company is developing PRX302 as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia, or BPH, commonly referred to as an enlarged prostate and as a treatment for localized low to intermediate risk prostate cancer. PRX302, a genetically modified recombinant protein, is delivered via ultrasound-guided injection directly into the prostate. The Company completed placebo-controlled Phase IIb clinical trial of PRX302 for BPH symptoms. The Company is also engaged in the ongoing and planned clinical development in BPH and localized prostate cancer for PLUS-1, a Phase III clinical trial of PRX302 for the treatment of the lower urinary tract symptoms of BPH.

Officers and directors

Lars G. Ekman M.D., Ph.D. Chairman of the Board
Age: 65
Randall E. Woods President, Chief Executive Officer, Director
Age: 63
Peter T. Slover CPA Chief Financial Officer
Age: 40
Allison J. Hulme Ph.D. Chief Operating Officer, Head - Research & Development
Age: 52
John Geltosky Ph.D. Independent Director
Age: 69
James L. Heppell Independent Director
Age: 59
Gerald T. Proehl Independent Director
Age: 56
Joseph L. Turner Jr. Independent Director
Age: 63